Familial Nasopharyngeal Carcinoma 6

Subject IndexAAcoustic neuritis, 281Acute/subacute adverse effects, 234Acute toxicity, 187, 208, 305Adenoid cystic carcinoma, 290Adenoids, 45Adenovirus-p53 (rAd-p53), 176, 177Adjuvant chemotherapy, 126, 127, 164Adolescent patients, 295–306Adriamycin, 194Age, 111Akt and Ras/MAPK pathways, 29Akt pathway. See Cellular signaling pathwaysAlkylating agents, 153Altered fractionated radiation, 126Altered fractionation, 143American Academy for Otolaryngology-Head and NeckSurgery (AAO-HNS), 215American Head and Neck Society (AHNS), 235American Joint Committee on Cancer (AJCC), 96, 309Amifostine, 278–279, 299Amphiregulin, 29Anatomy, 214–221– imaging, 81–83Anemia, 117–118, 271Angiogenesis, 32–33Anorexia, 305Anterolateral approach. See NasopharyngectomyAnthracyclines, 153, 269Antibody-dependent cellular cytotoxicity (ADCC), 104Anti-DNase, 106Anti-EBV antibody, 103–106Anti-EBV EA IgA. See Early antigenAnti-EBV VCA IgA. See Early antigenAnti-metabolites, 152Audiometry, 281Auditory tympanic tube. See Eustachian tubeBBamHI-A regions (BART miRNAs), 37BamHI A rightward transcripts (BART), 16, 17BART. See BamHI A rightward transcriptsBART miRNA, 37Basal cell carcinoma, 306Basaloid SCC, 75Base of skull, 318Basisphenoid, 81Betacellulin, 29Bevacizumab, 36, 156Biomarkers, 111– plasma tissue, 109–111Biopsies, 61, 234Bleomycin (BLEO), 153, 175, 184, 269, 301Brachytherapy, 123, 144, 242–244, 257, 259–261– HDR, 144– intracavitary, 144– LDR, 144Brainstem, 209, 286Bromodeoxyuridine (BrdU), 17, 18Buccopharyngeal fascia, 45Burkitt lymphoma (BL), 12CCA-9. See Carbonic anhydrase 9Cancer stem cells (CSC), 18, 20Capecitabine, 153, 190, 268Carbonic anhydrase 9 (CA-9), 156Carboplatin, 153, 172–173, 184, 270Carotid sheath, 255b-Catenin, 36Cellular signaling pathways, 16– NF-kB, 15, 16– Ras/MAPK, 16– Wnt pathway, 19Cervical adenopathy, 310Cetuximab, 32, 272Cetuximab (C-225), 29Chemosensitivity, 267Chemotherapy, 141, 163–164, 268–272, 299–301– adjuvant, 151, 193–195– concurrent, 168– maintenance, 153– neoadjuvant, 151– – preradiation chemotherapy, 304– palliative, 150– regimens– – BEC, 302– – CAPABLE, 269– – FXH, 35